{
  "meta": {
    "title": "Medicine_Neet_2025",
    "url": "https://brainandscalpel.vercel.app/medicine-neet-2025-a5cb2c72.html",
    "scrapedAt": "2025-11-30T13:02:40.991Z"
  },
  "questions": [
    {
      "text": "1. A patient came with complaints of palpitations and dyspnea for 4 hours. On ECG, he was found to have atrial fibrillation with no other cardiovascular symptoms. What is the next best step in management?",
      "choices": [
        {
          "id": 1,
          "text": "Ventricular rate control"
        },
        {
          "id": 2,
          "text": "Emergent cardioversion"
        },
        {
          "id": 3,
          "text": "Look for left atrial thrombus with carotid doppler"
        },
        {
          "id": 4,
          "text": "Anticoagulation"
        }
      ],
      "correct_choice_id": 1,
      "solution": "In the above scenario with atrial fibrillation, the patient is hemodynamically stable (no other cardiovascular symptoms) and hence, the next best step in management is ventricular rate control.<br><br>The treatment of atrial fibrillation depends on three things: the duration of symptoms, the severity of symptoms, and the risk of stroke. The patients who present within 48 hours of the onset of symptoms have a lower risk of an existing atrial thrombus and can be safely cardioverted. <br><br>The patient presenting within 48 hours (4 hours in this case) can be managed  by following the following algorithm:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/65affbb2429a470b9d5ebb1469a0b9f0x1280x2221.JPEG\" alt=\"Explanation Image\"><br><br>Those who present with an unknown or known onset of more than 48 hours should ideally be anticoagulated before cardioversion. This can be done in 2 ways, as shown below:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d2aabb966631485da12618f45b0bdc8fx1280x2207.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "2. A 40-year-old woman presents with dry eyes, dry mouth, and dry cough. She requires frequent sips of water while eating. Schirmer test was positive. Laboratory investigations revealed ANA, anti-Ro/SSA, and anti-La/SSB antibodies. What are the characteristic features seen in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Destruction of salivary glands due to neutrophilic infiltration"
        },
        {
          "id": 2,
          "text": "Malar rash and arthritis"
        },
        {
          "id": 3,
          "text": "Destruction of salivary glands and lacrimal glands due to lymphocytic infiltration"
        },
        {
          "id": 4,
          "text": "Amyloid deposition in salivary glands"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The given clinical features, along with the positive Schirmer’s test and the presence of ANA, Anti-Ro/SSA, and Anti-La/SSB antibodies, suggest a clinical suspicion of Sjögren’s disease. Salivary and Lacrimal glands are the major targets of this disease, where there is characteristic destruction of salivary glands and lacrimal glands due to lymphocytic infiltration, as shown in the image below:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/635d2dde600f43ddb224c7b34f38d9fbx720x538.PNG\" alt=\"Explanation Image\"><br><br>It is an autoimmune disorder that has a 10-20:1 Female-to-male incidence ratio. Lacrimal and salivary glands are the major targets of this disease, where there is a characteristic decrease in tears and saliva (sicca syndrome) due to lymphocytic infiltration and fibrosis of the lacrimal and salivary glands. The infiltrate contains predominantly activated CD4+ helper T cells and some B cells, including plasma cells.<br><br>Diagnosis by testing for antibodies against two ribonucleoprotein antigens- SS-A (Ro) and SS-B (La). Rheumatoid factor is seen in about 75% of the patients. ANA is also often detected on an immunofluorescence assay. A labial biopsy is the investigation of choice.<br><br>Other options: <br><br>Option A: Destruction of salivary glands due to neutrophilic infiltration can be seen in acute bacterial sialadenitis.<br><br>Option B: Malar rash and arthritis are seen in Systemic Lupus Erythematosus (SLE).<br><br>Option D: Amyloid deposition in salivary glands can be seen in amyloidosis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "3. A 20-year-old patient presented with salt craving, skin pigmentation, hyponatremia, hyperkalemia, and metabolic acidosis. What is the likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Cushing syndrome"
        },
        {
          "id": 2,
          "text": "Addison's disease"
        },
        {
          "id": 3,
          "text": "Pheochromocytoma"
        },
        {
          "id": 4,
          "text": "Conn syndrome"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The given clinical features of salt craving, skin pigmentation, along with hyponatremia, hyperkalemia, and metabolic acidosis, are suggestive of primary adrenal insufficiency, as seen in Addison's disease.<br><br>Addison's disease is most commonly caused by autoimmune adrenalitis. It may also result from the destruction of the adrenal cortex due to hemorrhage, infection, or infiltration.<br><br>The symptoms of adrenal insufficiency are as follows:<br><br>* Glucocorticoid deficiency leads to:<br><br>* Fatigue, lack of energy<br><br>* Weight loss, anorexia<br><br>* Myalgia<br><br>* Hypoglycemia <br><br>* Low blood pressure, postural hypotension<br><br>* Mineralocorticoid deficiency leads to:<br><br>* Abdominal pain, nausea, vomiting<br><br>* Dizziness, postural hypotension<br><br>* Low blood pressure, postural hypotension<br><br>* Hyponatremia<br><br>* Hyperkalemia<br><br>* Adrenal androgen deficiency leads to dry and itchy skin, loss of libido <br><br>* The hyperpigmentation of sun-exposed areas results from excess ACTH (adrenocorticotropic hormone) secretion, which occurs in response to decreased adrenal cortical hormones.<br><br>The diagnosis of adrenal insufficiency is confirmed using the short cosyntropin test. Acute adrenal insufficiency requires immediate management with intravenous saline and close cardiac monitoring. Treatment primarily involves glucocorticoid replacement, with mineralocorticoid therapy added in cases of primary adrenal insufficiency.<br><br>Other options:<br><br>Option A: Cushing syndrome results from chronic exposure to excess glucocorticoids. It presents with weight gain, central obesity, hypertension, and hypokalemia. Other clinical features include thin, brittle skin with easy bruising, purple stretch marks, diabetes, dyslipidemia, and osteopenia.<br><br>Option C: Pheochromocytoma is a catecholamine-secreting tumor derived from the chromaffin cells of the adrenal medulla. It most commonly presents as a classic triad of intermittent headache, palpitation, and profuse sweating, along with hypertension.<br><br>Option D: Conn syndrome refers to primary hyperaldosteronism. It usually results from an aldosterone-secreting adenoma. Excess aldosterone leads to increased sodium and water retention and potassium excretion, resulting in hypokalemia, volume expansion, and hypertension.<br><br>Pearl PM1419: Causes of Adrenocortical Insufficiency<br><br>Primary adrenal insufficiency:<br><br>* Anatomical destruction of gland<br><br>* Autoimmune (Addison's disease)<br><br>* Isolated autoimmune adrenalitis (polygenic)<br><br>* Infections - HIV, tuberculosis, fungi<br><br>* Surgical removal<br><br>* Acute hemorrhagic necrosis (Waterhouse-Friderichsen syndrome)<br><br>* Amyloidosis, sarcoidosis, hemochromatosis<br><br>* Metastatic carcinoma<br><br>* Cytotoxic agents – mitotane<br><br>* Enzyme inhibitors – metyrapone, ketoconazole<br><br>* Congenital adrenal hypoplasia<br><br>* Autoimmune polyendocrinopathy syndrome type 1 (AIRE1 gene on 21q22)<br><br>* Autoimmune polyendocrinopathy syndrome type 2 (polygenic)<br><br>* X-linked adrenal hypoplasia (DAX1 gene on Xp21)<br><br>* Adrenoleukodystrophy (ALD gene on Xq28)<br><br>Secondary adrenal insufficiency:<br><br>Hypopituitarism due to hypothalamic or pituitary disease<br><br>* Neoplasm<br><br>* Infiltration (sarcoidosis)<br><br>* Infection (tuberculosis, pyogenic, fungal)<br><br>Suppression of HPA axis<br><br>* By endogenous steroids from tumor<br><br>* By exogenous steroids",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "4. A female patient with a known case of bronchial asthma is on levosalbutamol and Ipratropium bromide metered-dose inhalers. She now reports frequent nocturnal symptoms, including wheezing and breathlessness that wake her up several times a week. What is the most appropriate next step in management?<br><br>LABA - Long-Acting Beta-Agonist",
      "choices": [
        {
          "id": 1,
          "text": "Increase dose of Salbutamol nebulization"
        },
        {
          "id": 2,
          "text": "Add Corticosteroids orally"
        },
        {
          "id": 3,
          "text": "Add LABA and inhaled corticosteroid (ICS)"
        },
        {
          "id": 4,
          "text": "Add Montelukast"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Since the patient has frequent nocturnal symptoms with wheezing and breathlessness that wake her up several times a week, the most appropriate next step of management is the addition of Long-Acting Beta-Agonist (LABA) and inhaled corticosteroid (ICS).<br><br>Drugs used in the treatment of bronchial asthma:<br><br>Bronchodilators<br><br>* Beta-2 sympathomimetics: Salmeterol, Formoterol<br><br>* Methylxanthines: Theophylline, Aminophylline<br><br>* Anticholinergics: Ipratropium bromide, Tiotropium bromide<br><br>Anti-inflammatory<br><br>* Corticosteroids (Inhalational): Beclomethasone, Budesonide, Fluticasone<br><br>* Corticosteroids (Systemic): Prednisolone, Hydrocortisone<br><br>* Mast cell stabilizers: Sodium cromoglycate, Ketotifen<br><br>* Leukotriene antagonists: Montelukast, Zafirlukast<br><br>* anti-IgE - Omalizumab<br><br>* anti-IL5 - Mepolizumab, Reslizumab<br><br>* anti-IL4 receptor - Dupilumab<br><br>* anti-TSLP (thymic stromal lymphopoietin) - Tezepelumab<br><br>As per GINA guidelines, ICS/Formoterol (LABA) is used as reliever therapy in all steps of asthma therapy. A stepwise approach is used for the treatment of Asthma, as shown in the image below.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/85c161c684ed4b2497f98dd47d4fc9b2x1280x3955.JPEG\" alt=\"Explanation Image\"><br><br>Important Update - According to GINA 2019, Short-acting beta 2 agonists (SABA) have no role in treating acute exacerbations. Even though SABA provides short-term relief of symptoms, there is strong evidence that SABA-only treatment increases the risk of exacerbations. GINA now recommends that symptom-driven (in mild asthma), a daily dose of ICS (inhaled corticosteroids) containing treatment be used to reduce the risk of serious exacerbations. This is said to be the most important change in asthma management in 30 years.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "5. A patient is newly diagnosed with HIV and has had fever for 2 weeks with cough and dyspnea. Chest X-Ray showed cavitatory lesions in the upper lobe. The patient is to be started on treatment. What is the appropriate strategy?<br><br>CD4 cells = 150/μL",
      "choices": [
        {
          "id": 1,
          "text": "Start ART after completing Anti-TB therapy"
        },
        {
          "id": 2,
          "text": "Start Anti-TB therapy after 2 weeks of ART"
        },
        {
          "id": 3,
          "text": "Start ART after 2 weeks of Anti-TB therapy"
        },
        {
          "id": 4,
          "text": "Start both ART and Anti-TB therapy immediately"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The most appropriate strategy for this patient is starting ART after 2 weeks of anti-TB therapy.<br><br>In a patient with HIV and TB, start ATT first and then start ART as soon as ATT is tolerated (between 2 weeks and 2 months) by the patient. This is done to avoid immune reconstitution inflammatory syndrome (IRIS). In case of TB meningitis, ART initiation is delayed by at least 4 weeks.<br><br>Patients with HIV-related TB may experience a temporary paradoxical exacerbation of symptoms and radiographic manifestations of TB after starting ATT. This occurs as a result of immune reconstitution due to simultaneous administration of ART and ATT.<br><br>It is characterized by high fever, lymphadenopathy, expanding intrathoracic lesions, and worsening of chest X-ray findings. Diagnosis should be made only after ruling out treatment failure and other infections. For severe cases, prednisone 1-2mg/kg is used for 1-2 weeks and then gradually tapered.<br><br>However, in patients with CD4 <50/μL, the benefits of administering ART immediately after initiating ATT outweigh the risks of IRIS, and therefore, ART should be started as early as possible.<br><br>Pearl PM2302: Opportunistic Infections/HIV related conditions and ART initiation<br><br><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action </td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia) </td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems) </td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment </td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "6. A patient who had undergone knee replacement surgery 7 days back, now presents with complaints of sudden shortness of breath and tachycardia. What is the next appropriate diagnostic test?",
      "choices": [
        {
          "id": 1,
          "text": "D Dimer"
        },
        {
          "id": 2,
          "text": "Chest X-ray"
        },
        {
          "id": 3,
          "text": "CT pulmonary angiography"
        },
        {
          "id": 4,
          "text": "Ventilation/Perfusion scan"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The given clinical scenario of a patient with complaints of sudden shortness of breath, tachycardia, after knee replacement surgery 7 days back suggests the probable diagnosis to be pulmonary embolism. The next appropriate diagnostic test is CT pulmonary angiography.<br><br>Pulmonary embolism (PE) should be suspected in a patient who complains of sudden breathlessness and hemoptysis after prolonged immobilisation. Well's point score helps to estimate the clinical likelihood of PE. <br><br>CT of the chest with intravenous contrast is the principal imaging test for the diagnosis of PE. It can provide exquisite detail, with ≤1 mm of resolution during a short breath-hold. It also helps to visualise the chambers of the heart. In patients who do not have a pulmonary embolism, it can also help in identifying alternative diagnoses like emphysema, pulmonary fibrosis, pulmonary mass, etc.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ba2dd6cc045540539ac5fd04c28403e1x1280x2263.JPEG\" alt=\"Explanation Image\"><br><br>Other options:<br><br>Option A: D-dimer rises in PE because of the breakdown of fibrin by plasmin. Normal levels of D-dimer rule out the possibility of PE, but it is not specific. D-dimer levels also increase in patients with myocardial infarction, pneumonia, sepsis, cancer, postoperative state, and those in the second or third trimester of pregnancy.<br><br>Option B: Chest X-ray can be normal in PE, and hence it is not very reliable.<br><br>Option D: Ventilation/Perfusion scan has become a second-line diagnostic test for PE in patients who cannot tolerate intravenous contrast. Small particulate aggregates of albumin labelled with a gamma-emitting radionuclide are injected intravenously and are trapped in the pulmonary capillary bed. The perfusion scan defect indicates absent or decreased blood flow.<br><br>Pearl PM2392: Clinical prediction for pulmonary embolism: Well’s, Modified Well’s and Pulmonary Embolism Rule out Criteria (PERC)<br><br><table>\n<tbody>\n<tr>\n<td><strong>Signs/symptoms</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Clinical signs of DVT</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Diagnosis other than pulmonary embolism is less likely</td>\n<td>3</td>\n</tr>\n<tr>\n<td>Heart rate &gt;100 bpm</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Immobilization for &gt;3 days or surgery in the last 4 weeks</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Past history of DVT/pulmonary embolism</td>\n<td>1.5</td>\n</tr>\n<tr>\n<td>Hemoptysis</td>\n<td>1</td>\n</tr>\n<tr>\n<td>Malignancy</td>\n<td>1</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Three-level score probability:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Well's criteria</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Low</td>\n<td>&lt;2</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>2-6</td>\n</tr>\n<tr>\n<td>High</td>\n<td>&gt;6</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Two-level score probability:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Modified Well's criteria</strong></td>\n<td><strong>Score</strong></td>\n</tr>\n<tr>\n<td>Pulmonary embolism unlikely</td>\n<td>≤4</td>\n</tr>\n<tr>\n<td>Pulmonary embolism likely</td>\n<td>&gt;4 </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> <br><br>Pulmonary embolism rule out criteria (PERC):<br><br>This is a quick OPD/casualty tool to rule out pulmonary embolism in patients with low clinical probability. It comprises eight clinical variables. If the patient meets all eight criteria, there is no need for further investigations. The variables include: <br><br>* Age <50 years<br><br>* Heart rate <100 bpm<br><br>* SpO2 ≥95%<br><br>* No unilateral leg swelling<br><br>* No hemoptysis<br><br>* No recent trauma or surgery<br><br>* No history of venous thromboembolism<br><br>* No use of hormonal therapy.<br><br>Pearl PM0584: Chest X Ray signs in pulmonary embolism<br><br>Westermark's sign: Focal area of oligemia (decreased vascular markings) distal to the embolism. <br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/1320503c26a8431b903e7e15089c8ed4x720x655.JPEG\" alt=\"Explanation Image\"><br><br>Hampton's hump: Peripherally placed wedge-shaped or dome-shaped opacity due to infarction of lung tissue. <br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5faac4b6986f4b6da649d4ca027f99b3x1063x874.JPEG\" alt=\"Explanation Image\"><br><br>Palla's sign: Increased size of the right descending pulmonary artery with a sausage-like appearance. <br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/9d6849e258104848bfc976a72abaae15x1069x804.JPEG\" alt=\"Explanation Image\"><br><br>Fleishner sign: enlarged pulmonary artery.<br><br>Melting sign: an infarct shows rapid clearing in contrast to pneumonic consolidation.<br><br>McConnell's sign (indirect sign of PE seen in transthoracic echo): hypokinesis of the right ventricular free wall with normal motion of the right ventricle apex.<br><br>Knuckle or sausage’ sign: dilatation of the pulmonary artery, proximal to the embolus with collapse or constriction of the distal arteries resulting in an abrupt tapering of these arteries.  <br><br>Note - A normal chest X-ray does not rule out pulmonary embolism in a patient with unexplained acute tachypnea or hypoxemia.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "7. A patient came with a history of dyspnea, fatigue, and palpitations for 6 months. He gave a history of acute rheumatic fever in childhood. On examination, JVP was elevated, irregularly irregular pulse, hepatomegaly, and pedal edema were present. There was a left parasternal heave. On auscultation, opening snap with MDM murmur was present. All are true in this case except:<br><br>RHF - Right Heart Failure\nMDM - Mid Diastolic Murmur",
      "choices": [
        {
          "id": 1,
          "text": "RHF features seen"
        },
        {
          "id": 2,
          "text": "Absent a wave on JVP"
        },
        {
          "id": 3,
          "text": "Presystolic accentuation of MDM is a hallmark of this condition"
        },
        {
          "id": 4,
          "text": "Increased risk of stroke is present"
        }
      ],
      "correct_choice_id": 3,
      "solution": "All of the given statements are true except that presystolic accentuation of MDM is a hallmark of this condition.<br><br>The given clinical features are consistent with atrial fibrillation in a patient with mitral stenosis. Pre-systolic accentuation of the mid-diastolic murmur that is characteristically seen in mitral stenosis is absent in the case of Atrial Fibrillation.<br><br>On auscultating a patient with mitral stenosis, a mid-diastolic murmur with presystolic accentuation and an opening snap is typically heard. The presystolic accentuation is due to the atrial contraction forcing blood through the stenosed mitral valve. The presystolic accentuation disappears and marks the setting in of atrial fibrillation. The absence of an atrial kick corresponds to the absence of a fourth heart sound.<br><br>The list of findings consistent with atrial fibrillation is as follows:<br><br>* Absent p wave on ECG <br><br>* Absent a wave (option B) on JVP<br><br>* Absent S4 (fourth heart sound) on auscultation<br><br>* Absent presystolic accentuation in the patient with mitral stenosis on auscultation<br><br>In addition, elevated left atrial pressure in mitral stenosis leads to pulmonary venous hypertension, increased afterload on the right ventricle, and eventual right heart failure (option A). <br><br>Furthermore, atrial fibrillation causes irregular and uncoordinated atrial contractions, resulting in stasis of blood in the atria. This predisposes to thrombus formation, which can embolize and cause ischemic stroke; hence, the patient had an increased risk for stroke (option D).",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "8. A patient presents with morning stiffness and tests positive for anti-CCP antibodies. Which of the following histological features is most characteristic of the underlying disease?",
      "choices": [
        {
          "id": 1,
          "text": "Pannus formation with synovial hypertrophy"
        },
        {
          "id": 2,
          "text": "Basophilic deposition in the synovial cavity"
        },
        {
          "id": 3,
          "text": "Cartilage serration with osteophyte formation"
        },
        {
          "id": 4,
          "text": "Tophi with monosodium urate crystals"
        }
      ],
      "correct_choice_id": 1,
      "solution": "The given clinical scenario with morning stiffness and anti-CCP antibody positivity suggests Rheumatoid Arthritis. This condition is characteristically associated with pannus formation due to synovial hypertrophy.<br><br>Histopathology of Rheumatoid Arthritis shows the presence of pannus, which consists of macrophages, fibroblast-like synovial cells, and inflammatory cells. Its formation over the cartilage results from synovial proliferation and hyperplasia.<br><br>Histopathological findings in Rheumatoid Arthritis include:<br><br>* Synovial hyperplasia and proliferation<br><br>* Dense inflammatory infiltrates of CD4+ T cells, B cells, plasma cells, dendritic cells, and macrophages<br><br>* Increased vascularity due to angiogenesis<br><br>* Fibrinopurulent exudate on synovial and joint surfaces<br><br>* Osteoclastic activity leading to bone erosion and subchondral cyst formation<br><br>* Pannus formation<br><br>As the disease advances, pannus bridges opposing bony surfaces, leading to cartilage destruction and eventually fibrous ankylosis.<br><br>Other Options:<br><br>Option B: Basophilic deposition in the synovial cavity occurs in Calcium Pyrophosphate Crystal Deposition Disease (Pseudogout).<br><br>Option C: Cartilage erosion with osteophyte formation is seen in Osteoarthritis.<br><br>Option D: Tophi with monosodium urate crystals are characteristic of Gout.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "9. A 30-year-old female notices weakness in her right hand and difficulty while kneading dough. On examination, right arm tone and power are decreased, and reflexes are sluggish. What is the site of the lesion?",
      "choices": [
        {
          "id": 1,
          "text": "Posterior limb of the internal capsule"
        },
        {
          "id": 2,
          "text": "Right corticospinal tract in cervical cord"
        },
        {
          "id": 3,
          "text": "Anterior horn cell of the cervical spinal cord"
        },
        {
          "id": 4,
          "text": "Left medullary pyramid"
        }
      ],
      "correct_choice_id": 3,
      "solution": "As per the given clinical findings, the site of the lesion is the anterior horn cell of the cervical spinal cord.<br><br>The given clinical findings, such as weakness in the hand, hypotonia, decreased power, and sluggish reflexes, are indicative of a lower motor neuron (LMN) lesion. Hence, the most likely site of lesion in this patient is the anterior horn cell of the cervical spinal cord.<br><br>LMN weakness occurs due to disorders affecting the lower motor neurons in the brainstem, the anterior horn cells of the spinal cord, or due to dysfunction of their axons.<br><br>In contrast, upper motor neuron (UMN) weakness results from lesions affecting the upper motor neurons or their descending pathways in the spinal cord. This is characterized by increased muscle tone with spasticity, hyperactive reflexes, and a positive Babinski sign.<br><br>Lesions at the following sites can lead to UMN palsy:<br><br>* Motor cortex (precentral gyrus) - contralateral weakness<br><br>* Posterior limb of internal capsule - contralateral hemiparesis (option A)<br><br>* Brainstem (pons, medullary pyramid) - contralateral weakness with or without cranial nerve deficits (option D)<br><br>* Corticospinal tract in the spinal cord - ipsilateral spastic paresis below the lesion (option B)<br><br>Pearl PM2510: Features of Motor Neuron Lesions<br><br><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Upper Motor Neuron Lesion</strong></p>\n</td>\n<td>\n<p><strong>Lower Motor Neuron Lesion</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Upper motor neuron typically refer to corticospinal tract neurons that innervate spinal motor neurons, but they can also include brainstem neurons that control spinal motor neurons</p>\n</td>\n<td>\n<p>Lower motor neurons are those whose axons terminate on skeletal muscles</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Little or no muscle wasting → weakness of relatively large group of muscles</p>\n</td>\n<td>\n<p>Muscle atrophy → muscle weakness of an individual and specific muscle</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Hypertonia</p>\n</td>\n<td>\n<p>Hypotonia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Increased or exaggerated deep tendon reflexes (hyperreflexia)</p>\n</td>\n<td>\n<p>Hyporeflexia or areflexia</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Spasticity</p>\n</td>\n<td>\n<p>Flaccidity</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Positive Babinski sign (abnormal plantar extensor reflex)</p>\n</td>\n<td>\n<p>Fasciculations</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "10. A 55-year-old patient presents with shortness of breath. Arterial blood gas analysis reveals the following- pH: 7.22, PaCO₂: 66 mmHg, PaO₂: 45 mmHg, HCO₃⁻: 26 mEq/L. What is the most likely acid-base disorder?",
      "choices": [
        {
          "id": 1,
          "text": "Metabolic alkalosis"
        },
        {
          "id": 2,
          "text": "Respiratory acidosis"
        },
        {
          "id": 3,
          "text": "Respiratory alkalosis"
        },
        {
          "id": 4,
          "text": "Metabolic acidosis"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The most likely acid-base disorder in the patient is Respiratory acidosis.<br><br>Interpretation of the ABG:<br><br>Step 1: A pH of 7.22 (normal: 7.35-7.45) signifies acidosis.<br><br>Step 2: An elevated pCO2 of 66 mmHg (normal: 35-45 mmHg) along with a low pH signifies respiratory acidosis.<br><br>Step 3: The plasma HCO3- is 26 mEq/L (normal: 22-28 mEq/L). This high HCO3- is due to compensation.<br><br>Step 4: The expected compensatory increase in HCO3- can be calculated using the following formula:\nIncrease in HCO3- = 0.1 X ΔpCO2 (the patient has an acute onset of dyspnoea, hence this is taken as acute respiratory acidosis)\nIncrease in HCO3- = 0.1 X (66 - 40) = 2.6 mEq/L (40 mmHg is the optimal value for pCO2)\nExpected HCO3- = 24 + 2.6 = 26.6 mEq/L (24 mmHg is the optimal value for HCO3-)<br><br>HCO3- measured is 26 mEq/L (which is less than the expected value), indicating that compensation is partial.<br><br>Thus, the ABG shows respiratory acidosis with partial metabolic compensation.<br><br>Pearl PM1521: Causes of Metabolic Acidosis<br><br><table>\n<tbody>\n<tr>\n<td>High Anion-Gap Metabolic Acidosis (MUDPILES)</td>\n<td>Normal Anion-Gap Metabolic Acidosis (FUSED CAR)</td>\n</tr>\n<tr>\n<td><strong>M</strong>ethanol</td>\n<td><strong>F</strong>istula pancreatic</td>\n</tr>\n<tr>\n<td><strong>U</strong>remia (Renal failure - Acute or Chronic)</td>\n<td><strong>U</strong>reterosigmoidostomy</td>\n</tr>\n<tr>\n<td><strong>D</strong>iabetic ketoacidosis</td>\n<td><strong>S</strong>mall bowel fistula</td>\n</tr>\n<tr>\n<td><strong>P</strong>araldehyde</td>\n<td><strong>E</strong>xtra chloride (Hyperalimentation)</td>\n</tr>\n<tr>\n<td><strong>I</strong>ron tablets, INH</td>\n<td><strong>D</strong>iarrhea</td>\n</tr>\n<tr>\n<td><strong>L</strong>actic acidosis</td>\n<td><strong>C</strong>arbonic anhydrase inhibitor (acetazolamide)</td>\n</tr>\n<tr>\n<td><strong>E</strong>thylene glycol</td>\n<td><strong>A</strong>ddison's disease</td>\n</tr>\n<tr>\n<td><strong>S</strong>alicylates</td>\n<td><strong>R</strong>enal tubular acidosis</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM2409: Acid-Base Balance - Normal Values<br><br><table>\n<tbody>\n<tr>\n<td>Component</td>\n<td>Normal Range</td>\n<td>Optimal Value</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>7.35 - 7.45</td>\n<td>7.4</td>\n</tr>\n<tr>\n<td>HCO<sub>3</sub><sup>-</sup> </td>\n<td>22 - 28 mEq/L </td>\n<td> 24 mEq/L</td>\n</tr>\n<tr>\n<td>pCO<sub>2</sub></td>\n<td>35 - 45 mmHg</td>\n<td>40 mmHg </td>\n</tr>\n<tr>\n<td>Anion gap</td>\n<td>6 - 12 mEq/L</td>\n<td>&lt;10 mEq/L</td>\n</tr>\n<tr>\n<td>O<sub>2</sub> saturation</td>\n<td colspan=\"2\">&gt; 95%</td>\n</tr>\n<tr>\n<td>pO<sub>2</sub></td>\n<td colspan=\"2\">75 - 100 mmHg  </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "11. A patient presented with chest discomfort and palpitations. ECG shows PSVT (Paroxysmal Supraventricular Tachycardia). What is the drug used in the prophylaxis for this condition?",
      "choices": [
        {
          "id": 1,
          "text": "IV Esmolol"
        },
        {
          "id": 2,
          "text": "IV Adenosine"
        },
        {
          "id": 3,
          "text": "Oral Verapamil"
        },
        {
          "id": 4,
          "text": "Oral Phenytoin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "Oral Verapamil is the drug that is used for the prophylaxis of PSVT.<br><br>Verapamil and Diltiazem are used in both acute treatment and prophylaxis of PSVT. They are class IV anti-arrhythmics. They block Ca2+ channels, resulting in slowing SA node automaticity and AV nodal conduction velocity. Additionally, they also decrease cardiac contractility and reduce blood pressure. However, they do not affect intraventricular conduction. They are primarily used to terminate attacks of PSVT and to control the ventricular rate in atrial fibrillation and flutter.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/16c4534451f244bf9c43d74c07268356x510x812.PNG\" alt=\"Explanation Image\"><br><br>Other options:<br><br>Option A: IV Esmolol is a quick and short-acting β1-blocker and is used for emergency control of ventricular rate in Atrial Fibrillation or Atrial Flutter.<br><br>Option B: IV Adenosine is the drug of choice for the acute treatment of PSVT.<br><br>Option D: Oral phenytoin is a Class IB antiarrhythmic, having action similar to Mexilitene, and is used in the treatment of ventricular arrhythmia.<br><br>Pearl PM0115: Anti-arrhythmic drugs<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/7d6c4d5ed4a54f70b2030d71f3d06969x1280x1697.JPEG\" alt=\"Explanation Image\"><br><br><table>\n<tbody>\n<tr>\n<td>\n<p><span><strong>Class of antiarrhythmic drugs </strong></span></p>\n</td>\n<td>\n<p><span> </span></p>\n<p><span><strong>Mechanism of action</strong></span></p>\n</td>\n<td>\n<p><span><strong>Effect on action potential duration</strong></span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class I</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IA</strong></span></p>\n<p><span>Procainamide</span></p>\n<p><span>Quinidine</span></p>\n<p><span>Disopyramide</span></p>\n</td>\n<td>\n<p><span> </span></p>\n<p><span>Na+ channel blockers with significant K<sup>+</sup> channel blocking property</span></p>\n<p><span> </span></p>\n</td>\n<td>\n<p><span>Prolonged</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IB</strong></span></p>\n<p><span>Lidocaine</span></p>\n<p><span>Mexiletine</span></p>\n</td>\n<td><span>Na+ channel blockers with K<sup>+</sup> channel opening property </span></td>\n<td>\n<p><span>Shortened or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IC</strong></span></p>\n<p><span>Flecainide</span></p>\n<p><span>Propafenone</span></p>\n<p><span>Moricizine</span></p>\n</td>\n<td><span>Na+ channel blockers with negligible K<sup>+</sup> channel blocking property </span></td>\n<td>\n<p><span>Variable or no effect</span></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class II</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Propranolol</span></p>\n<p><span>Esmolol</span></p>\n</td>\n<td><span>β- blockers</span></td>\n<td><span>- </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class III</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Amiodarone, dronedarone</span></p>\n<p><span>Dofetilide</span></p>\n<p><span>Sotalol</span></p>\n<p><span>Ibutilide</span></p>\n<p><span>Vernakalant</span></p>\n</td>\n<td><span>K<sup>+</sup> channel blockers </span></td>\n<td><span>Prolonged </span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Class IV</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Verapamil</span></p>\n<p><span>Diltiazem</span></p>\n</td>\n<td><span>Ca<sup>2+</sup> channel blockers</span></td>\n<td><span>-</span></td>\n</tr>\n<tr>\n<td>\n<p><span><strong>Miscellaneous</strong></span></p>\n</td>\n<td><span> </span></td>\n<td><span> </span></td>\n</tr>\n<tr>\n<td>\n<p><span>Adenosine</span></p>\n</td>\n<td><span>Activates adenosine receptors</span></td>\n<td><span>Shortened</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Digoxin</span></p>\n</td>\n<td><span>Na<sup>+</sup>-K<sup>+</sup> ATPase inhibitor</span></td>\n<td><span>Increases AV node refractoriness</span></td>\n</tr>\n<tr>\n<td>\n<p><span>Magnesium</span></p>\n</td>\n<td><span>Unknown</span></td>\n<td><span>-</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "12. A 19-year-old female patient who is a known case of Type 1 Diabetes Mellitus presents to the casualty with diffuse weakness. She had stopped insulin 1 day before presenting, as per her mother. On examination, BP was 80/60 mmHg, her plasma glucose was 720 mg/dL, Na⁺ - 126 mEq/L, and K⁺ - 4.3 mEq/L. Which of the following is not a step in the management of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "NS 0.9%"
        },
        {
          "id": 2,
          "text": "NS 3%"
        },
        {
          "id": 3,
          "text": "Give IV insulin"
        },
        {
          "id": 4,
          "text": "Monitor K⁺ for any increase"
        }
      ],
      "correct_choice_id": 2,
      "solution": "NS 3% is not used in the management of the given condition.<br><br>The given clinical scenario, along with the laboratory values and a history of type 1 diabetes mellitus, is suggestive of diabetic ketoacidosis (DKA), a serious complication of uncontrolled diabetes.<br><br>Diabetic ketoacidosis is the most serious complication of type 1 diabetes mellitus. Clinical manifestations of diabetic ketoacidosis include:<br><br>* Dehydration, tachypnea with deep, sighing respiration (Kussmaul breathing)<br><br>* Nausea, vomiting, and abdominal pain that may mimic an acute abdominal condition<br><br>* Confusion, drowsiness, and coma in severe cases.<br><br>Initial management includes management of the airway, breathing, and circulation (ABC). Following that, an emergency assessment is done, which includes:<br><br>* Immediate measurement of blood glucose, blood or urine ketones, serum electrolytes, and blood gases<br><br>* Assessment of the level of consciousness.<br><br>* Two peripheral intravenous (IV) lines should be inserted.<br><br>The goal of therapy is to correct dehydration, correct acidosis, reverse ketosis, and gradually bring blood glucose concentration to near normal. Monitor for acute complications, and identify and treat any precipitating event.<br><br>Fluid replacement should always begin before starting insulin therapy. One or more boluses of 0.9% saline (option A) at 10-20 mL/kg are given to restore peripheral circulation. A bolus of 0.1 U/kg IV regular insulin (option C) should be given after the initial replacement of fluids. Insulin therapy with 0.05–0.1 U/kg/hr must begin at least 1 hour after starting fluid replacement therapy. Insulin of 0.05 U/kg/hr can be considered if the pH is > 7.15.<br><br>Potassium replacement is given only when potassium is <5.5 mmol/L. In rare cases of hypokalemia with potassium <3.0 mmol/L, defer insulin treatment. Electrolytes, especially K⁺, must be monitored (option D) every 4 hours for the first 24 hours.<br><br>Bicarbonate administration is not recommended except for treatment of severe acidosis (pH < 6.9) or in cases of life-threatening hyperkalemia.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/882104e5b6d14f9b9542379fc1da9ee1x656x1476.PNG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "13. A 40-year-old male patient presented with complaints of drowsiness and was admitted for evaluation. Sodium was found to be 98 mEq/L, which was corrected to 110 mEq/L with 3% saline in 24 hours. The patient recovered for a while and had an altered sensorium later. Now, he developed quadriparesis and bilateral conjugate gaze palsy. Which is the investigation to be done in this case?",
      "choices": [
        {
          "id": 1,
          "text": "CSF analysis"
        },
        {
          "id": 2,
          "text": "Brainstem auditory evoked potential"
        },
        {
          "id": 3,
          "text": "MRI brain"
        },
        {
          "id": 4,
          "text": "EEG"
        }
      ],
      "correct_choice_id": 3,
      "solution": "MRI Brain (Magnetic Resonance Imaging) is the investigation to be done in the given case.<br><br>This is a typical history of sudden correction of hyponatremia leading to central pontine myelinolysis, a common complication associated with the treatment of hyponatremia. MRI Brain is the investigation that is used to make a diagnosis of this condition.<br><br>Central pontine myelinolysis/ Osmotic demyelination syndrome is seen due to rapid correction of chronic hyponatremia (hyponatremia lasting for more than 48 hrs). It results in the efflux of organic osmolytes from brain cells, which reduces intracellular osmolality and osmotic gradient, and water entry. <br><br>Rapid correction of hyponatremia, i.e., >8–10 mEq/L in 24 h (12 mEq/L in this case) or 18 mEq/L in 48 h, causes hypertonic stress in astrocytes within the brain, causing demyelination without inflammation at the base of the pons, with relative sparing of axons and nerve cells.<br><br>Clinically, patients present one or more days after overcorrection of hyponatremia with paraparesis or quadriparesis, diplopia, a “locked-in syndrome,” dysphagia, dysarthria with/without loss of consciousness. <br><br>MRI is useful in establishing the diagnosis and may also identify partial forms that present as confusion, dysarthria, and/or disturbances of conjugate gaze without paraplegia.<br><br>Prevention can be done by restoration of severe hyponatremia gradually, i.e., by ≤10 mmol/L (10 mEq/L) within 24 h and ≤20 mmol/L (20 mEq/L) within 48 h.<br><br>The image shows the MRI finding of central pontine myelinolysis with axial fat-saturated T2-Weighted MRI showing hyperintense signal in the central pons (trident sign or omega sign).<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/97db1af1f9ec4e40ad21a8e7dfbbb7e8x477x547.PNG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "14. A patient with HIV with a CD4 count of 250 cells/mm³ is newly diagnosed to have rifampicin resistance TB. Which of the following is the appropriate regimen, and what should be monitored?",
      "choices": [
        {
          "id": 1,
          "text": "Isoniazid, Ethambutol, Steptomycin, Pyrazinamide for 9 months and optic neuritis"
        },
        {
          "id": 2,
          "text": "Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 6 months and immune reconstitution syndrome"
        },
        {
          "id": 3,
          "text": "Isoniazid, Ethambutol, Levofloxacin, Pyrazinamde for 6 months and hepatotoxicity"
        },
        {
          "id": 4,
          "text": "Isoniazid, Ethambutol, Clarithromycin, Pyrazinamide for 12 months and pyridoxine deficiency"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The most appropriate treatment for the given condition is Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 6 months. The patient should be monitored for the development of immune reconstitution syndrome.<br><br>This is a case of HIV infection with multidrug-resistant tuberculosis (MDR-TB). The BPaLM regimen, consisting of Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin for 6 months, is the new treatment protocol recommended by the WHO for MDR-TB.<br><br>In HIV-positive patients newly diagnosed with TB, initiating anti-tubercular therapy (ATT) can trigger immune reconstitution inflammatory syndrome (IRIS). This is a paradoxical worsening of symptoms and radiographic manifestations due to immune recovery after simultaneous initiation of ART and ATT.<br><br>Clinically, patients may develop high fever, lymphadenopathy, expanding intrathoracic lesions, and worsening chest X-ray findings. The diagnosis is made only after excluding treatment failure and other opportunistic infections.<br><br>Severe cases of IRIS are managed with corticosteroids such as prednisone (1-2 mg/kg for 1-2 weeks), followed by gradual tapering. To reduce the risk of IRIS, the timing of ART initiation should be optimized. ATT is started first, and ART is added once ATT is tolerated, usually between 2 weeks and 2 months.<br><br>In patients with CD4 counts <50/μL, ART should be started as early as possible, since the benefits outweigh the risk of IRIS. In those with higher CD4 counts, ART can be delayed, but should still be introduced within 8 weeks (2 months) of starting ATT<br><br>Pearl PM1720: ATT Regimen for TB Patients<br><br>As per the latest recommendations from National Tuberculosis Elimination Programme (NTEP), treatment of TB is now based primarily on drug susceptibility testing. This is irrespective of new cases, previously treated cases or recurrent TB cases. \nAll cases of TB are treated with Drug Sensitive TB Regimen, as long as the patient is sensitive to isoniazid and rifampicin. (No classification into category I or II)<br><br><table>\n<tbody>\n<tr>\n<td><strong>Type of TB Case</strong></td>\n<td><strong>Intensive Phase</strong></td>\n<td><strong>Continuation Phase</strong></td>\n</tr>\n<tr>\n<td>New and previously treated cases (H and R sensitive)</td>\n<td>2 months HRZE</td>\n<td>4 months HRE (Only HR as per WHO guidelines)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Classification based on drug resistance. <br><br>The cases are classified as:<br><br>* Mono-resistant (MR): A TB patient who is resistant to one 1st line anti-TB drug only.<br><br>* Poly-Drug Resistant (PDR): A TB patient, who is resistant to more than one 1st line anti-TB drug, other than Rifampicin and isoniazid. <br><br>* Rifampicin Resistant (RR): A TB patient who is resistant to rifampicin with or without resistance to other drugs. Patients, who have rifampicin resistance, should be managed as if they are an MDR TB case.<br><br>* Multi-Drug Resistant (MDR): A TB patient who is resistant to both isoniazid and rifampicin.<br><br>* Extensively Drug-Resistant (XDR): A MDR TB patient who is additionally resistant to a fluoroquinolone (ofloxacin, levofloxacin, or moxifloxacin) and at least one additional group A drug (as of 2021, these are bedaquiline and linezolid)<br><br>Standard DR TB regimen<br><br><table>\n<tbody>\n<tr>\n<td><strong>Regimen class</strong></td>\n<td><strong>Drugs</strong></td>\n<td><strong>Comments</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/ poly-drug resistant TB regimen</strong></td>\n<td>Lfx R E Z for 6 months</td>\n<td>\n<p>6 months long</p>\n<p>Oral drugs only</p>\n</td>\n</tr>\n<tr>\n<td><strong>BPaLM regime (New MDR regime by WHO)</strong></td>\n<td>Bdq Pa Lzd Mfx for 6 months</td>\n<td>\n<p>6 months long</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter oral bedaquiline regime (Shorter MDR)</strong></td>\n<td>\n<p><strong>Intensive Phase:</strong></p>\n<p>Lfx Bdq(6 months) Cfz Z Hh E Eto for 4-6 months</p>\n<p><strong>Continuation phase:</strong></p>\n<p>Lfx Cfz Z E for 5 months</p>\n</td>\n<td>\n<p>9-11 months long totally</p>\n<p>Injectables used in Intensive phase.</p>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Bdq(6 months or longer) Lfx Lzd Cfz Cs </td>\n<td>\n<p>18-20 months long</p>\n<p>Oral drugs only</p>\n<p>This regimen is used for XDR TB patients for 20 months.</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br> \nCriteria for patients to receive standard Drug Resistant TB regimen:<br><br><table>\n<tbody>\n<tr>\n<td><strong>Standard Drug Resistant TB regimen</strong></td>\n<td><strong>Inclusion criteria</strong></td>\n<td><strong>Exclusion criteria</strong></td>\n</tr>\n<tr>\n<td><strong>H mono-resistant/poly-drug resistant TB regimen</strong></td>\n<td><strong>Isoniazid resistant</strong> TB with <strong>rifampicin sensitive</strong></td>\n<td>No specific criteria</td>\n</tr>\n<tr>\n<td><strong>BPaLM regimen (New MDR TB regimen by WHO)</strong></td>\n<td>\n<ol>\n<li><strong>MDR/RR-TB</strong> </li>\n<li>Those with <strong>confirmed</strong> pulmonary TB and all forms of extrapulmonary TB (except for TB involving CNS, osteoarticular, and miliary TB).</li>\n<li>Patients <strong>&gt;14 years of age.<br/></strong></li>\n</ol>\n</td>\n<td>\n<p>Pregnant and lactating women</p>\n<p>Patients with uncontrolled cardiac arrhythmia that requires medication</p>\n</td>\n</tr>\n<tr>\n<td><strong>9- 11 months shorter MDR TB regimen</strong></td>\n<td>Patient with <strong>rifampicin resistant</strong> pulmonary or extra pulmonary TB</td>\n<td>Non drug sensitivity test based criteria:\n<ul>\n<li>Pregnancy</li>\n<li>Any extra pulmonary disease in PLHIV</li>\n<li>Disseminated meningeal or central nervous system TB</li>\n<li>Intolerance to any drug in the shorter MDR TB regimen</li>\n</ul>\nDrug sensitivity test based criteria:\n<ul>\n<li>If DST/DRT result for FQ or SLI is resistant (XDR TB)</li>\n<li>Presence of InhA mutation</li>\n<li>Resistant to Z </li>\n</ul>\n</td>\n</tr>\n<tr>\n<td><strong>Longer MDR TB regimen</strong></td>\n<td>Patients in whom <strong>shorter MDR TB regimen cannot be considered</strong> due to any reason</td>\n<td>None</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Legend<br><br>FQ: Fluoroquinolone<br><br>SLI: Second Line Injectable<br><br>PLHIV: People Living with HIV<br><br>Lfx: Levofloxacin<br><br>Pa: Pretomanid<br><br>H: Isoniazid<br><br>Hh: High Dose Isoniazid<br><br>R: Rifampicin<br><br>E: Ethambutol<br><br>Z: Pyrazinamide<br><br>Mfx: Moxifloxacin<br><br>Km: Kanamycin<br><br>Am: Amikacin<br><br>Eto: Ethionamide<br><br>Cfz: Clofazimine<br><br>Bdq: Bedaquiline<br><br>Lzd: Linezolid<br><br>Cs: Cycloserine<br><br>Pearl PM2302: Opportunistic Infections/HIV related conditions and ART initiation<br><br><table>\n<tbody>\n<tr>\n<td>Clinical scenario</td>\n<td>Action </td>\n</tr>\n<tr>\n<td>Any undiagnosed active infection with fever</td>\n<td>Diagnose and treat first; start Anti-Retroviral Therapy (ART) when stable</td>\n</tr>\n<tr>\n<td>Tuberculosis (TB)</td>\n<td>Start TB treatment first; start ART as soon as possible after 2 weeks and before 2 months. For those with CD4 less than 50/cmm, start ART within 2 weeks Caution is needed for PLHIV with TB meningitis, since immediate ART is associated with more severe adverse events than initiating ART 2 months after the start of TB treatment</td>\n</tr>\n<tr>\n<td>\n<p>Pneumocystis pneumonia (PCP)</p>\n</td>\n<td>Treat PCP first; start ART when PCP treatment is completed</td>\n</tr>\n<tr>\n<td>Invasive fungal diseases: Oesophageal candidiasis, penicilliosis, histoplasmosis</td>\n<td>Start treatment for oesophageal candidiasis first; start ART as soon as the patient can swallow comfortably. Treat penicilliosis, and histoplasmosis first; start ART when the patient is stabilized or opportunistic infection treatment is completed.</td>\n</tr>\n<tr>\n<td>Cryptococcal meningitis</td>\n<td>Treat cryptococcal meningitis. ART initiation should be deferred until there is evidence of sustained clinical response to anti-fungal therapy and after 4 weeks of induction and consolidation treatment with amphotericin B containing regimen.</td>\n</tr>\n<tr>\n<td>Bacterial pneumonia</td>\n<td>Treat pneumonia first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Malaria</td>\n<td>Treat malaria first; start ART when treatment is completed</td>\n</tr>\n<tr>\n<td>Acute diarrhoea which may reduce absorption of ART</td>\n<td>Diagnose the cause and treat diarrhoea first; start ART when diarrhoea is stabilized or controlled</td>\n</tr>\n<tr>\n<td>Non-severe anaemia (Hb&lt; 9 g/dl)</td>\n<td>Start ART if no other causes for anaemia are found (HIV is often the cause of anaemia) </td>\n</tr>\n<tr>\n<td>Skin conditions such as PPE and seborrhoeic dermatitis, psoriasis, HIV-related exfoliative dermatitis</td>\n<td>Start ART (ART may resolve these problems) </td>\n</tr>\n<tr>\n<td>Suspected Mycobacterium Avium Complex (MAC), Cryptosporidiosis and Microsporidiosis</td>\n<td>Start ART (ART may resolve these problems)</td>\n</tr>\n<tr>\n<td>Cytomegalovirus retinitis</td>\n<td>Start treatment for CMV urgently and start ART after 2 weeks of CMV treatment </td>\n</tr>\n<tr>\n<td>Toxoplasmosis</td>\n<td>Treat toxoplasmosis; start ART after 6 weeks of treatment and when the patient is stabilized</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "15. A patient with Type 2 Diabetes Mellitus complains of numbness and burning sensations in the extremities. On examination, he has absent ankle reflexes and has no sensation to touch, vibration, or pain in his lower limbs. The loss of sensation in his extremities has a stocking distribution. What type of neuropathy is associated?",
      "choices": [
        {
          "id": 1,
          "text": "Autonomic neuropathy"
        },
        {
          "id": 2,
          "text": "Mononeuropathy"
        },
        {
          "id": 3,
          "text": "Symmetric distal polyneuropathy"
        },
        {
          "id": 4,
          "text": "Proximal motor neuropathy"
        }
      ],
      "correct_choice_id": 3,
      "solution": "As per the given clinical scenario and the patient’s symptoms, this is a case of symmetric distal polyneuropathy.<br><br>Distal symmetric polyneuropathy is the most common form of diabetic neuropathy. It presents with distal sensory loss and pain in a stocking-and-glove distribution and predisposes to foot ulceration. As the disease progresses, pain subsides while sensory deficits persist, and the patient develops motor weakness. On clinical examination, there may be loss of ankle reflexes, impaired position sense, muscle atrophy, or foot drop.<br><br>Other options:<br><br>Option A: Autonomic neuropathy is a common complication and presents with postural hypotension, silent myocardial infarction, hypoglycemia unawareness, erectile dysfunction, overflow incontinence, gastroparesis, and enteropathy with constipation or diarrhea.<br><br>Option B: Mononeuropathy can affect peripheral nerves (median, ulnar, radial) and cranial nerves (especially oculomotor). Mononeuropathy multiplex can also occur.<br><br>Option D: Proximal motor neuropathy (diabetic amyotrophy) involves the lumbar plexus or femoral nerve, leading to severe pain in the thigh or hip. It is associated with hip flexor or extensor weakness.<br><br>Pearl PM2075: Sensory Loss In peripheral Neuropathies<br><br>Symmetrical Sensory Loss<br><br>* Cryptogenic or idiopathic sensory polyneuropathy (CSPN)<br><br>* Diabetes mellitus and other metabolic disorders<br><br>* Drugs and toxins<br><br>* Familial (HSAN), CMT, amyloidosis<br><br>* Inflammatory demyelinating polyneuropathy (GBS and CIDP) <br><br>Asymmetrical Sensory Loss<br><br>* Cancer (paraneoplastic)<br><br>* Sjögren’s syndrome<br><br>* Idiopathic sensory neuronopathy (possible GBS variant)<br><br>* Cisplatin and other chemotherapeutic agents<br><br>* Vitamin B6 toxicity<br><br>* Multifocal CIDP, vasculitis, cryoglobulinemia, amyloidosis, sarcoid, infectious (leprosy, Lyme, hepatitis B, C, or E, HIV, CMV), tumor infiltration <br><br>* Compressive mononeuropathy, plexopathy, or radiculopathy<br><br>* Polyradiculopathy or plexopathy due to diabetes mellitus<br><br>* Cryptogenic or idiopathic sensory polyneuropathy (CSPN)",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "16. A patient presented with skin tightening and arthralgia. Raynaud's phenomenon was positive. Lab investigations showed ANA positive and Anti-Scl-70 (Anti-topoisomerase-1) antibody. The presence of which of the following conditions is associated with this Anti-Scl-70 antibody?",
      "choices": [
        {
          "id": 1,
          "text": "Calcinosis cutis"
        },
        {
          "id": 2,
          "text": "Gastric Antral Vascular Ectasia"
        },
        {
          "id": 3,
          "text": "Interstitial Lung Disease"
        },
        {
          "id": 4,
          "text": "Myositis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The given clinical scenario, along with ANA and Anti-Scl-70 positivity, is suggestive of systemic sclerosis. Anti-Scl-70 positivity in this disease is associated with a high risk for interstitial lung disease (ILD).<br><br>Systemic sclerosis (SSc), also called scleroderma, is an autoimmune rheumatic disease with a 4:1 female predominance. A wide spectrum of clinical features is seen in SSc. Early in the disease, patients may experience Raynaud’s phenomenon, with episodic color changes of the fingers in response to cold or stress, and arthralgia due to joint involvement.<br><br>The skin initially becomes puffy with nonpitting edema, and as the disease progresses, it becomes indurated, thickened, and fixed to underlying structures, resulting in sclerodactyly and characteristic skin tightening. Severe pruritus, vasospasm, and digital ulceration may also be present.<br><br>Facial features include mask-like facies due to tight, waxy skin and lack of wrinkles, an expressionless face, mat-like telangiectases, microstomia (fish mouth appearance), perioral furrowing, and a beak-like nose.<br><br>Most patients have dysphagia and gastroesophageal reflux from esophageal involvement, and fibrosis of the skin and internal organs can significantly affect quality of life.<br><br>Immunologically, the nucleolar ANA pattern, with fluorescent spots within the nucleus, is most often seen in SSc. Anti-topoisomerase I (Scl-70) and anti-RNA polymerase III antibodies are associated with diffuse cutaneous systemic sclerosis and a higher risk of ILD, while other autoantibodies linked with ILD include anti-U3-RNP, anti-PM/Scl, anti-Ro52, and anti-U11/U12-RNP.<br><br>Other options:<br><br>Option A: Calcinosis cutis is classically seen in limited cutaneous systemic sclerosis and is associated with anti-Centromere autoantibodies. <br><br>Option B: Gastric Antral Vascular Ectasia (GAVE) is associated with anti-RNA polymerase III autoantibodies.<br><br>Option D: Myositis in a patient with systemic sclerosis is associated with anti-Ku and anti-U1-RNP autoantibodies.<br><br>Pearl PM2428: Autoantibodies Seen in Autoimmune Diseases<br><br><table>\n<tbody>\n<tr>\n<td><strong>         Autoantibody</strong></td>\n<td><strong>Associated disease</strong></td>\n</tr>\n<tr>\n<td>Antinuclear (ANA)</td>\n<td>\n<p>SLE (non-specific)</p>\n</td>\n</tr>\n<tr>\n<td>Anticardiolipin, lupus anticoagulant</td>\n<td>SLE, APLA syndrome</td>\n</tr>\n<tr>\n<td>Anti-ds DNA, anti-Smith</td>\n<td>SLE</td>\n</tr>\n<tr>\n<td>Anti-histone</td>\n<td>Drug-induced Lupus</td>\n</tr>\n<tr>\n<td>Anti-U1 RNP</td>\n<td>Mixed connective tissue disease</td>\n</tr>\n<tr>\n<td>Rheumatoid factor, anti-CCP</td>\n<td>Rheumatoid arthritis</td>\n</tr>\n<tr>\n<td>Anti-Ro/SSA, Anti-La/SSB</td>\n<td>Sjögren’s syndrome</td>\n</tr>\n<tr>\n<td>Anti-Scl-70 (anti-DNA topoisomerase)</td>\n<td>Diffuse scleroderma</td>\n</tr>\n<tr>\n<td>Anticentromere</td>\n<td>CREST syndrome</td>\n</tr>\n<tr>\n<td>Anti-SRP, Anti-Mi-2, Anti-Jo-1</td>\n<td>Polymyositis, Dermatomyositis</td>\n</tr>\n<tr>\n<td>p-ANCA/MPO</td>\n<td>Churg Strauss syndrome</td>\n</tr>\n<tr>\n<td>c-ANCA</td>\n<td>Wegener (Granulomatosis with polyangiitis)</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Pearl PM1947: Diffuse Cutaneous Systemic Sclerosis Versus Limited Cutaneous Systemic Sclerosis<br><br><table>\n<tbody>\n<tr>\n<td><strong>Characteristic feature</strong></td>\n<td><strong>Diffuse cutaneous systemic sclerosis</strong></td>\n<td><strong>Limited cutaneous systemic sclerosis</strong></td>\n</tr>\n<tr>\n<td>Skin involvement</td>\n<td>\n<p>Rapid progression</p>\n<p>Involvement of the skin areas <strong>proximal</strong> <strong>to the knees or elbows</strong> or over the anterior chest, trunk, or abdomen</p>\n</td>\n<td>\n<p>Slow progression</p>\n<p>Limited to face and skin <strong>distal</strong> <strong>to the elbows and knees</strong></p>\n<p> </p>\n<p> </p>\n</td>\n</tr>\n<tr>\n<td>Raynaud’s phenomenon</td>\n<td>\n<p>Less severe</p>\n<p> </p>\n<p><strong>Short history</strong> </p>\n</td>\n<td>\n<p>More severe; commonly associated with critical limb ischemia.</p>\n<p><strong>Long history</strong> </p>\n</td>\n</tr>\n<tr>\n<td>Musculoskeletal</td>\n<td><strong>Severe arthralgia</strong>, carpal tunnel syndrome, and tendon friction rubs</td>\n<td><strong>Mild</strong> arthralgia</td>\n</tr>\n<tr>\n<td>Pulmonary manifestation</td>\n<td>Interstitial lung disease more common</td>\n<td>Pulmonary artery hypertension (PAH) is equal in both</td>\n</tr>\n<tr>\n<td>Scleroderma renal crisis</td>\n<td>Occurs usually &lt;4 years of disease onset</td>\n<td>Very rare</td>\n</tr>\n<tr>\n<td>Calcinosis cutis</td>\n<td>Less common</td>\n<td>More common &amp; prominent</td>\n</tr>\n<tr>\n<td>Auto-antibodies</td>\n<td>\n<p><strong>Anti-topoisomerase I</strong> (Scl-70)</p>\n<p>anti-RNA polymerase III</p>\n</td>\n<td><strong>Anti centromere</strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/35bb13425bb64e78b9164796e0c2fc29x1280x2412.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "17. A 68-year-old male with Type 2 Diabetes Mellitus and an HbA1c of 8.2% is being evaluated. He has chronic heart failure with an ejection fraction of 35% and is currently taking metformin and glargine insulin. Which of the following medications is most appropriate to add for glycemic control in this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Empagliflozin"
        },
        {
          "id": 2,
          "text": "Sitagliptin"
        },
        {
          "id": 3,
          "text": "Glibenclamide"
        },
        {
          "id": 4,
          "text": "Pioglitazone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "Empagliflozin is the most appropriate drug to add for glycemic control in this patient.<br><br>This patient has type 2 diabetes mellitus with poor glycemic control (elevated HbA1c) and chronic heart failure with reduced ejection fraction (HFrEF). Empagliflozin, an SGLT-2 inhibitor, is the most suitable choice here, as it not only improves glycemic control but also provides significant cardiovascular and renal protection.<br><br>It acts in the proximal renal tubules by blocking SGLT-2, leading to increased urinary glucose excretion. This mechanism is independent of insulin and contributes to lower blood glucose levels. Promoting natriuresis and mild diuresis, it helps reduce intravascular volume and cardiac workload.<br><br>In addition, it is associated with modest weight loss, blood pressure reduction, and has been shown to reduce mortality from cardiovascular causes in diabetic patients with heart failure.<br><br>Adverse effects include dehydration, urinary tract and genital mycotic infections, euglycemic diabetic ketoacidosis, and in some cases fractures or amputation risk (particularly with canagliflozin), as well as possible bladder cancer risk with dapagliflozin.<br><br>Other options : <br><br>Option B: Sitagliptin is a DPP-4 inhibitor that potentiates the action of GLP-1. It is orally absorbed, undergoes minimal metabolism, and is largely excreted unchanged in the urine. Dose adjustment is required in renal impairment, but not in liver disease. Sitagliptin is generally well tolerated. Nausea may occur, but it is not a prominent side effect.<br><br>Option C: Glibenclamide (Glyburide) is a sulfonylurea and stimulates insulin release by inhibiting the ATP-sensitive K+ channel in beta cells of the pancreas. They are readily absorbed from the gastrointestinal tract and therefore can be given orally.<br><br>Option D: Pioglitazone is an activator of the peroxisome proliferator-activated receptor γ (PPARγ), which is involved in the regulation of genes related to glucose and lipid metabolism. Its adverse effects include increased incidence of heart failure (hence, contraindicated in this patient), peripheral edema, weight gain, macular edema, and osteoporosis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "18. A patient presented with right-sided weakness, aphasia, and irregularly irregular pulse for last 2 hours. On CT brain, no hemorrhage can be seen. What should be the next best step in management?",
      "choices": [
        {
          "id": 1,
          "text": "Warfarin"
        },
        {
          "id": 2,
          "text": "Transesophageal Echocardiography"
        },
        {
          "id": 3,
          "text": "rtPA"
        },
        {
          "id": 4,
          "text": "LMWH"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The next best step in the management of this condition is rtPA administration.<br><br>Sudden-onset hemiparesis, aphasia & irregularly irregular pulse with no signs of hemorrhage on CT indicate ischemic stroke secondary to atrial fibrillation in this patient. Intravenous thrombolysis using a recombinant tissue plasminogen activator - rtPA should be immediately administered to patients with ischemic stroke who arrive in the window period, i.e., within 3-4.5 hours (2 hours in the given case) of symptom onset.<br><br>Intravenous Recombinant Tissue Plasminogen Activator (IV rtPA) - Alteplase 0.9 mg/kg up to a maximum of 90 mg, 10% as a bolus, the remainder as infusion over 60 min is given. Tenecteplase 0.25 mg/kg IV bolus over 5s is also used. IV rtPA is given only after checking for the indications and the contraindications for its administration. <br><br>The following flowchart explains the management and patient flow in a case of an acute stroke:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2a160b9247c34291b74f452a92eae64cx1280x3849.JPEG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "19. An elderly patient presents with increased frequency of breathing and weakness. ABG is given. What is the likely diagnosis? <br><br>* pH = 7.3<br><br>* pCO2 = 44 mmHg<br><br>* pO2 = 85 mmHg<br><br>* HCO3- = 16 mEq/L<br><br>* Na+ = 132 mEq/L<br><br>* Cl- = 86 mEq/L<br><br>* Base excess = -12 mEq/L",
      "choices": [
        {
          "id": 1,
          "text": "Acute metabolic alkalosis with AG 16 mEq/L"
        },
        {
          "id": 2,
          "text": "Acute respiratory acidosis with AG 16 mEq/L"
        },
        {
          "id": 3,
          "text": "Acute metabolic acidosis with AG 30 mEq/L"
        },
        {
          "id": 4,
          "text": "Chronic Respiratory acidosis with AG 30 mEq/L"
        }
      ],
      "correct_choice_id": 3,
      "solution": "The most likely acid-base disorder in the patient is acute metabolic acidosis with an anion gap (AG) of 30 mEq/L.<br><br>Interpretation of the ABG:<br><br>Step 1: A pH of 7.3 signifies acidosis.<br><br>Step 2: The plasma HCO3- is 16 mEq/L below normal (22 - 28 mEq/L), and the pCO2 is 44 mmHg, which lies in the normal range (35-45 mmHg). This, along with low pH, signifies metabolic acidosis.<br><br>Step 3: The expected compensatory decrease in pCO2 can be calculated using the following formula:\nDecrease in pCO2 = 1.25 X Δ HCO3- \nDecrease in pCO2  = 1.25 X (24 - 16) = 10 mmHg\nExpected pCO2  = 40 - 10 = 30 mmHg\nThe measured pCO2 is 44 mmHg (which is more than the expected value), indicating that there is no respiratory compensation.<br><br>Step 4: The anion gap can be calculated using the following formula:\nAnion Gap = [Na+] - ([Cl-] + [HCO3-])\nAnion Gap = 132 - (16 + 86) = 30 mEq/L<br><br>Thus, the ABG shows metabolic acidosis with an anion gap of 30 mEq/L.<br><br>Pearl PM2409: Acid-Base Balance - Normal Values<br><br><table>\n<tbody>\n<tr>\n<td>Component</td>\n<td>Normal Range</td>\n<td>Optimal Value</td>\n</tr>\n<tr>\n<td>pH</td>\n<td>7.35 - 7.45</td>\n<td>7.4</td>\n</tr>\n<tr>\n<td>HCO<sub>3</sub><sup>-</sup> </td>\n<td>22 - 28 mEq/L </td>\n<td> 24 mEq/L</td>\n</tr>\n<tr>\n<td>pCO<sub>2</sub></td>\n<td>35 - 45 mmHg</td>\n<td>40 mmHg </td>\n</tr>\n<tr>\n<td>Anion gap</td>\n<td>6 - 12 mEq/L</td>\n<td>&lt;10 mEq/L</td>\n</tr>\n<tr>\n<td>O<sub>2</sub> saturation</td>\n<td colspan=\"2\">&gt; 95%</td>\n</tr>\n<tr>\n<td>pO<sub>2</sub></td>\n<td colspan=\"2\">75 - 100 mmHg  </td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "20. A 35-year-old female with hyperpigmentation, hypotension, and hyponatremia is diagnosed with Addison's disease. Which of the following hormones is responsible for her hyperpigmentation?",
      "choices": [
        {
          "id": 1,
          "text": "Aldosterone"
        },
        {
          "id": 2,
          "text": "Cortisol"
        },
        {
          "id": 3,
          "text": "ACTH"
        },
        {
          "id": 4,
          "text": "Renin"
        }
      ],
      "correct_choice_id": 3,
      "solution": "ACTH (adrenocorticotropic hormone) is the hormone responsible for hyperpigmentation in a patient with Addison's disease.<br><br>In primary adrenal insufficiency (Addison's disease) due to the loss of glucocorticoid and mineralocorticoid secretion, the negative feedback to the HPA (Hypothalamic-Pituitary-Adrenal) axis is lost, leading to excessive secretion of ACTH and MSH (Melanocyte-stimulating hormone). The main cause of hyperpigmentation is excess ACTH, which has a similar effect as MSH and stimulates the melanocytes for melanin formation.<br><br>The image below shows hyperpigmentation associated with Addison's disease:<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/33e6ed3e341b4d2ea5981d8e1f4b21a6x720x1443.PNG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "21. A 65-year-old male presented with fever, cough, and chest pain. Identify the lesion in the given Chest X-ray.",
      "choices": [
        {
          "id": 1,
          "text": "Right upper lobe consolidation"
        },
        {
          "id": 2,
          "text": "Right lung collapse"
        },
        {
          "id": 3,
          "text": "Right upper lobe malignancy"
        },
        {
          "id": 4,
          "text": "Right upper lobe abscess"
        }
      ],
      "correct_choice_id": 1,
      "solution": "The given chest X-ray shows right upper lobe consolidation.<br><br>The given clinical scenario of fever, cough, and chest pain suggests pneumonia. The chest X-ray shows an opacity in the right upper zone of the lung with a sharply defined lower border likely corresponding to the superior margin of the horizontal fissure, without tracheal deviation. These findings are consistent with right upper lobe consolidation.<br><br>Other options:<br><br>Option B: In right upper lobe collapse, the horizontal fissure shifts superiorly and medially toward the hilum, becoming concave. There is tracheal deviation to the right, along with compensatory hyperinflation of the right middle and lower lobes.<br><br>Option C: Lung malignancy usually appears as an irregular mass. It may be associated with collapse or consolidation, calcifications, or lymphadenopathy.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4f5ec48c5da6453aaec43c7d11595301x1280x974.JPEG\" alt=\"Explanation Image\"><br><br>Option D: A lung abscess typically presents as an irregular mass-like lesion with cavitation, often containing an air-fluid level.<br><br><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d66957e4079d426289337753fb532871x720x654.PNG\" alt=\"Explanation Image\">",
      "explanation_video": "",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/8d868e2a284145f0a33b4ff0cc0f5824.JPEG"
      ],
      "explanation_images": []
    },
    {
      "text": "22. A 25-year-old female patient with diagnosed recurrent migraine despite Sumatriptan, has 3-5 episodes/week and presents with features of anxiety and palpitations. There is no clinical neck swelling, no history of coronary artery disease; however, there is a family history of CHD. She reports experiencing chest tightness after taking the medication. What is the most appropriate agent to add for migraine prophylaxis?",
      "choices": [
        {
          "id": 1,
          "text": "Topiramate"
        },
        {
          "id": 2,
          "text": "Propranolol"
        },
        {
          "id": 3,
          "text": "Naratriptan"
        },
        {
          "id": 4,
          "text": "Ergotamine"
        }
      ],
      "correct_choice_id": 2,
      "solution": "The most appropriate agent to be added for migraine prophylaxis in this patient is Propranolol.<br><br>Drugs used in the prophylaxis of migraine include:<br><br>* Beta-blockers: Propranolol<br><br>* Calcium channel blocker: Flunarizine (Verapamil and Nimodipine have no role)<br><br>* Antidepressants: Amitriptyline, Venlafaxine (SSRIs such as Fluoxetine are not used)<br><br>* Anticonvulsants: Valproate, Topiramate<br><br>* 5-HT2 antagonist: Pizotifen<br><br>* CGRP antagonists: Erenumab, Fremanezumab, Galcanezumab, Eptinezumab<br><br>Other modalities of preventive treatment include:<br><br>* Greater occipital nerve block<br><br>* Onabotulinum toxin A<br><br>* Supraorbital transcutaneous stimulation<br><br>Propranolol is contraindicated in patients with severe asthma, COPD, peripheral vascular disease, severe bradycardia, and heart blocks. In this case, the patient does not have a history of coronary artery disease. The chest tightness experienced after taking the medication is most likely a side effect of sumatriptan rather than coronary heart disease. Hence, propranolol is not contraindicated in this patient.<br><br>Moreover, Propranolol will also be beneficial in addressing palpitations and anxiety that are seen in the patient.<br><br>Other options:<br><br>Option A: Topiramate is less preferred in this patient as she is a woman of reproductive age and it has teratogenic potential. Valproate is also less preferred due to the same reason.<br><br>Option C: Naratriptan belongs to the same class as sumatriptan (Triptans), and hence, adding it for prophylaxis will not be beneficial and worsen her chest tightness.<br><br>Option D: Ergotamine is a non-selective 5-HT agonist that is used in acute attacks of migraine and not for prophylaxis.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "23. A 14-year-old developed rapid growth and had long legs and large hands, and coarse facial features. Which of the following tests are used to make a confirmatory diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Increased GH levels"
        },
        {
          "id": 2,
          "text": "Increased IGF1"
        },
        {
          "id": 3,
          "text": "No supression of GH after glucose administration"
        },
        {
          "id": 4,
          "text": "No suppression of IGF1 after glucose tolerance test"
        }
      ],
      "correct_choice_id": 3,
      "solution": "A confirmatory diagnosis of the given clinical condition can be made by observing no suppression of Growth Hormone (GH) after glucose administration.<br><br>The given scenario and the presence of rapid growth, long legs, large hands, and coarse facial features point towards a diagnosis of gigantism. An oral glucose tolerance test with GH levels is used to confirm gigantism.<br><br>Giagantism is a result of growth hormone hypersecretion due to a pituitary adenoma. It can also occur due to extra-pituitary lesions. If growth hormone hypersecretion occurs after the fusion of the growth plates at puberty, it leads to acromegaly. <br><br>75g of oral glucose load is administered to the patient. The growth hormone levels are measured within 1-2 hours after administration. Normally, GH should be suppressed to less than 0.4 µg/L after the oral glucose load. A failure of suppression of growth hormone confirms the diagnosis of gigantism/acromegaly. In some patients, growth hormone levels may demonstrate a paradoxical rise. <br><br>Age-matched IGF1 levels are used for screening the disease. IGF1 levels are increased (option B) in the case of acromegaly/gigantism.<br><br>Pearl PM1525: Tests for Acromegaly<br><br>Screening test:<br><br>The single best test for the diagnosis of acromegaly is the measurement of serum insulin-like growth factor-1 (IGF-1). A normal serum IGF-1 concentration is strong evidence that the patient does not have acromegaly.<br><br>Confirmatory test:<br><br>GH suppression test: 75 g of oral glucose (OGTT- oral glucose tolerance test) is administered to the patient. Blood GH levels are checked at 30, 60, 90, 120 min (i.e over 2 hours) after the glucose load. Normally, glucose suppresses GH and it falls to <1 ng/mL. If GH >1 ng/mL, it is diagnostic of acromegaly.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "24. Which of the following crystalloid infusions, when given in large quantities, is likely to cause hyperchloremic metabolic acidosis?",
      "choices": [
        {
          "id": 1,
          "text": "D5W"
        },
        {
          "id": 2,
          "text": "NS"
        },
        {
          "id": 3,
          "text": "RL"
        },
        {
          "id": 4,
          "text": "DNS"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Infusion of NS (0.9% Normal Saline) in large quantities can lead to hyperchloremic metabolic acidosis.<br><br>0.9% NaCl is isotonic normal saline, but this solution is neither chemically nor physiologically normal. It contains 9 grams of NaCl per liter. This translates to sodium and chloride concentrations of 154 mEq/L each (osmolality = 154 + 154 = 308 mOsm/L). This is higher than the normal chloride concentration in the body, i.e, 96-106 mEq/L. Due to high chloride concentration, the excessive infusion can lead to hyperchloremic metabolic acidosis.<br><br>The following table summarizes the composition, osmolarity, tonicity relative to blood, and pH of various intravenous fluids:<br><br><table>\n<tbody>\n<tr>\n<td><strong><span class=\"NEbTegrW\">Fl</span><span class=\"NEbTegrW\">uid</span></strong></td>\n<td><strong><span class=\"wPWLDiZy\">Com</span><span class=\"mOHCZvhR\">posi</span><span class=\"HhkFGNzZ\">tio</span><span class=\"ksQohXrQ\">n</span></strong></td>\n<td><strong><span class=\"TZYpstop\">Osm</span><span class=\"VkILWHGL\">ola</span><span class=\"bpgEMpNE\">rity</span> <br/><span class=\"IeOGFrFU\">(To</span><span class=\"iNkrymDu\">nici</span><span class=\"hOMVXAkF\">ty</span> <span class=\"zcewDAyX\">vs</span> <span class=\"QxJPIRzX\">Bloo</span><span class=\"LzmtvKgi\">d)</span></strong></td>\n<td><strong><span class=\"BaunwLFX\">Chlo</span><span class=\"VfMyDzyB\">ride</span> <span class=\"hGRRUyWi\">con</span><span class=\"qianBwNg\">cent</span><span class=\"NEbTegrW\">ra</span><span class=\"AVcBUXqU\">tio</span><span class=\"qaKsPdaM\">n</span></strong></td>\n<td><strong><span class=\"ZbIextEK\">pH</span></strong></td>\n</tr>\n<tr>\n<td><span class=\"YthNhiCH\">D5W</span> <br/><span class=\"hOMVXAkF\">(5%</span> <span class=\"ZbIextEK\">De</span><span class=\"tjpwxHLZ\">xt</span><span class=\"vFSRvtNN\">rose</span> <span class=\"VfMyDzyB\">Wat</span><span class=\"csLjYMgA\">er)</span></td>\n<td><span class=\"vFYejLqh\">5</span> <span class=\"LzmtvKgi\">g</span> <span class=\"vFSRvtNN\">de</span><span class=\"mYHmctFH\">xtro</span><span class=\"ZbIextEK\">se</span> <span class=\"gMHkFYEq\">/</span> <span class=\"lTklvIqO\">100</span> <span class=\"mvDnwIJA\">mL</span> <span class=\"mZPYdvRA\">wat</span><span class=\"rtJLypWc\">er</span></td>\n<td><span class=\"kAdIfMje\">278</span> <span class=\"NvlkrXsc\">mOsm</span><span class=\"viTlNjdn\">/L</span><br/><span class=\"aVWEnYfi\">(iso</span><span class=\"TUfSmwyU\">ton</span><span class=\"VfMyDzyB\">ic)</span></td>\n<td><span class=\"ToOXDWHF\">0</span></td>\n<td><span class=\"qYziHmia\">3.5</span> <span class=\"lRcxZIZM\">-</span> <span class=\"niKPdBJd\">5.5</span></td>\n</tr>\n<tr>\n<td><span class=\"LzmtvKgi\">NS</span><br/><span class=\"mYHmctFH\">(Nor</span><span class=\"niKPdBJd\">mal</span> <span class=\"OByOwxLU\">Sali</span><span class=\"TVvNmQxJ\">ne</span><span class=\"KWPqABZj\">)</span></td>\n<td>\n<p><span class=\"hgeBqGAL\">0.9</span> <span class=\"tOMBbQea\">g</span> <span class=\"KWPqABZj\">Na</span><span class=\"DCfhjlTJ\">Cl</span> <span class=\"tOMBbQea\">/</span> <span class=\"mQpMkuQQ\">100</span> <span class=\"YthNhiCH\">mL</span> <span class=\"jHXEcynu\">wat</span><span class=\"LOnKXbyK\">er</span></p>\n</td>\n<td><span class=\"NEbTegrW\">308</span> <span class=\"ZObQgOXW\">mOs</span><span class=\"rtJLypWc\">m/</span><span class=\"NvlkrXsc\">L</span><br/><span class=\"mZPYdvRA\">(i</span><span class=\"MTmfdgUK\">so</span><span class=\"RBUGyYma\">to</span><span class=\"AuNaBRRw\">ni</span><span class=\"CJATEGxc\">c)</span></td>\n<td><span class=\"HhkFGNzZ\">154</span> <span class=\"FbShZuAH\">mE</span><span class=\"EHWJqOAN\">q/</span><span class=\"yqnskkNB\">L</span></td>\n<td>\n<p><span class=\"aVWEnYfi\">4.5</span> <span class=\"BaunwLFX\">-</span> <span class=\"BaunwLFX\">7.0</span></p>\n</td>\n</tr>\n<tr>\n<td><span class=\"tcatFoNp\">RL</span><br/><span class=\"hXVRpiCi\">(Ri</span><span class=\"xolaXOvH\">ng</span><span class=\"JXwHPXqj\">er'</span><span class=\"xolaXOvH\">s</span> <span class=\"DCfhjlTJ\">Lac</span><span class=\"TVvNmQxJ\">tate</span><span class=\"DvvXuKNr\">)</span></td>\n<td><span class=\"VElmUUiK\">Na</span><sup><span class=\"ZbIextEK\">+</span></sup><span class=\"ZbIextEK\">:</span> <span class=\"bpgEMpNE\">131</span> <span class=\"BaunwLFX\">mE</span><span class=\"NvlkrXsc\">q/L</span><br/><span class=\"LOnKXbyK\">K</span><sup><span class=\"tixEGJEV\">+</span></sup><span class=\"mOHCZvhR\">:</span> <span class=\"iXRbpryE\">5</span> <span class=\"jHXEcynu\">mEq/</span><span class=\"cqJMLBjP\">L</span> <br/><span class=\"VuXIUSUx\">Ca</span><sup><span class=\"DCfhjlTJ\">2+</span></sup><span class=\"qxsdgvww\">:</span> <span class=\"ySYRtAKG\">4</span> <span class=\"qYziHmia\">mEq/</span><span class=\"lRcxZIZM\">L</span> <br/><span class=\"hGRRUyWi\">Cl</span><sup><span class=\"DCfhjlTJ\">−</span></sup><span class=\"mQpMkuQQ\">:</span> <span class=\"DvvXuKNr\">111</span> <span class=\"qianBwNg\">mEq/</span><span class=\"aVWEnYfi\">L</span><br/><span class=\"qYziHmia\">La</span><span class=\"etKnOLsO\">cta</span><span class=\"bpgEMpNE\">te:</span> <span class=\"LzmtvKgi\">29</span> <span class=\"NEbTegrW\">mEq</span><span class=\"MTmfdgUK\">/L</span></td>\n<td>\n<p><span class=\"NEbTegrW\">273</span> <span class=\"mvDnwIJA\">mO</span><span class=\"ySYRtAKG\">sm/L</span><br/><span class=\"JXwHPXqj\">(is</span><span class=\"ldfRkdig\">ot</span><span class=\"IeOGFrFU\">onic</span><span class=\"aVWEnYfi\">)</span></p>\n</td>\n<td><span class=\"YthNhiCH\">111</span> <span class=\"PmZizuQg\">mEq/</span><span class=\"VuXIUSUx\">L</span></td>\n<td><span class=\"BaunwLFX\">5.0</span> <span class=\"OByOwxLU\">-</span> <span class=\"yilHNiUg\">7.0</span></td>\n</tr>\n<tr>\n<td><span class=\"qaKsPdaM\">DNS</span><br/><span class=\"NEbTegrW\">(D</span><span class=\"oyzZOAcL\">ex</span><span class=\"NEbTegrW\">tros</span><span class=\"qianBwNg\">e</span> <span class=\"VuXIUSUx\">Norm</span><span class=\"JoKQRzzY\">al</span> <span class=\"JXwHPXqj\">Sali</span><span class=\"wPWLDiZy\">ne)</span></td>\n<td><span class=\"gMHkFYEq\">5%</span> <span class=\"YqLoPdPk\">Dext</span><span class=\"pujsARkD\">ro</span><span class=\"TZYpstop\">se</span> <span class=\"iXRbpryE\">+</span> <span class=\"CwINpMCD\">0.9%</span> <span class=\"kAdIfMje\">Na</span><span class=\"hXVRpiCi\">Cl</span></td>\n<td><span class=\"mvDnwIJA\">586</span> <span class=\"mvDnwIJA\">mOsm</span><span class=\"ADeloWis\">/L</span><br/><span class=\"FbShZuAH\">(h</span><span class=\"jHXEcynu\">yper</span><span class=\"iNkrymDu\">toni</span><span class=\"RBUGyYma\">c)</span></td>\n<td><span class=\"kAdIfMje\">154</span> <span class=\"AuNaBRRw\">mE</span><span class=\"EHWJqOAN\">q/L</span></td>\n<td><span class=\"AVcBUXqU\">3.5</span> <span class=\"CUTOuhej\">-</span> <span class=\"ZbIextEK\">6.5</span></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><br><br>Note: DNS can also cause hyperchloremic metabolic acidosis, but it is used less frequently compared to NS. In DNS, NS is mainly responsible for causing hyperchloremic metabolic acidosis, while the 5% dextrose component plays no significant role.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    },
    {
      "text": "25. A patient presents with bleeding due to factor IX deficiency. In which of the following conditions will you find an improvement after administering Vitamin K parenterally?",
      "choices": [
        {
          "id": 1,
          "text": "Pernicious anemia"
        },
        {
          "id": 2,
          "text": "Bile duct obstruction"
        },
        {
          "id": 3,
          "text": "Hepatitis A"
        },
        {
          "id": 4,
          "text": "Classical hemophilia"
        }
      ],
      "correct_choice_id": 2,
      "solution": "Vitamin K administration will lead to an improvement of bleeding manifestations in a patient with bile duct obstruction.<br><br>Factors II, VII, IX, and X are vitamin K-dependent factors, and the deficiency of vitamin K can lead to a deficiency in any of these factors. Vitamin K is a fat-soluble vitamin, and hence its absorption is impaired in bile duct obstruction. In this case, if vitamin K is administered parentrally, it will lead to an improvement in the bleeding manifestation.<br><br>Other options:<br><br>Option A: Pernicious anemia is caused due to autoimmune destruction of parietal cells, which leads to a deficiency in intrinsic factor, which plays an important role in the absorption of vitamin B12. Bleeding manifestations or factor IX deficiency are not associated with this disorder, and hence, vitamin K administration plays no role in its management.<br><br>Option C: Hepatitis A can lead to a decline in the synthetic function of the liver, leading to a deficiency in clotting factors. This is not caused by a deficiency of vitamin K, and hence administering vitamin K in a patient with hepatitis A will not improve the bleeding manifestations.<br><br>Option D: Classical hemophilia or hemophilia A is a genetic disorder in which there is a deficiency of factor VIII. In this, the ability of the body to produce factor VIII is impaired, and hence, vitamin K injection will not lead to improvement in this condition.",
      "explanation_video": "",
      "question_images": [],
      "explanation_images": []
    }
  ]
}